Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.

Group 1: Eli Lilly Overview - Eli Lilly is the most valuable healthcare company globally, with a market cap of approximately $950 billion, and its stock price has increased by 400% over the past five years, largely due to the success of its GLP-1 drugs, Mounjaro and Zepbound [1] Group 2: Amgen's Potential - Amgen is developing a GLP-1 drug called MariTide, which is an injectable treatment that may only need to be administered once a month, offering a more convenient option compared to weekly injectables like Mounjaro and Zepbound [3] - Clinical trials for MariTide indicate it can help individuals lose up to 20% of their body weight over a 52-week period, comparable to existing GLP-1 treatments [4] Group 3: Investment Considerations for Amgen - Amgen's stock has risen by 34% over the past five years and currently trades at a forward P/E multiple of 16, which is significantly lower than Eli Lilly's forward P/E of 32, suggesting Amgen may be undervalued [5][6] - The GLP-1 drug market is projected to exceed $150 billion within the next decade, indicating substantial growth potential for Amgen and other companies in this sector [6]